Oxo-MDV 3100 (Oxo-enzalutamide)

• CAT Number: C000404
• CAS Number: 1242137-18-3
• Molecular Formula: C₂₁H₁₆F₄N₄O₃
• Molecular Weight: 448.37
• Purity: ≥95%
• Synonyms: 4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-2,4-dioxo-1-imidazolidinyl]-2-fluoro-N-methylbenzamide; Enzalutamide Impurity
• Solubility: DMSO (Slightly), Methanol (Slightly)
• Appearance: White to Off-White Solid
• Storage: 4°C
• IUPAC Name: 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl]-2-fluoro-N-methylbenzamide
• InChI: InChI=1S/C21H16F4N4O3/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)
• InChIKey: BPEQXCBJXGZMSB-UHFFFAOYSA-N
• SMILES: CC1(C(=O)N(C(=O)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C

Oxo-MDV 3100 (Oxo-enzalutamide)(CAT: C000404) is a metabolite of enzalutamide, widely utilized in oncology research for its role in studying prostate cancer. As an androgen receptor (AR) antagonist, it provides insights into the mechanisms of AR inhibition and resistance in advanced prostate cancer therapy. This compound is instrumental in exploring drug metabolism, pharmacokinetics, and the development of next-generation AR-targeted treatments. With its high specificity and relevance to clinical contexts, Oxo-MDV 3100 is a valuable tool for advancing research into AR signaling pathways and improving therapeutic strategies for hormone-dependent cancers.